Viatar CTC Solutions Inc. announced financial results for the first quarter ended March 31, 2016. For the first quarter of 2016, the company reported $0 sales compared to sales of $9,970 in the comparable quarter of 2015. Total research &development expenses, including clinical and regulatory expenses, were $895,365 compared to $820,655 in the first quarter of 2016 and 2015 respectively. The company reported a net loss of $1,373,351 for the first quarter of 2016 compared to a net loss of $1,116,238 for the comparable period in 2015.